Literature DB >> 3036498

In vitro activity of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine against newly isolated clinical varicella-zoster virus strains.

M Baba, K Konno, S Shigeta, E De Clercq.   

Abstract

The highly potent and selective anti-DNA virus agent (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine [(S)-HPMPA] was found to inhibit in vitro the replication of a number of clinical varicella-zoster virus strains within the concentration range of 0.63-5.7 ng/ml. With a mean 50% inhibitory concentration of 1.8 ng/ml and selectivity index of 29000, (S)-HPMPA is one of the most potent and most selective varicella-zoster virus inhibitors discovered to date.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3036498     DOI： 10.1007/BF02018198

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN： 0722-2211            Impact factor:   3.267


  10 in total

1.  Improved yields of cell-free varicella-zoster virus.

Authors:  N J Schmidt; E H Lennette
Journal:  Infect Immun       Date:  1976-09       Impact factor: 3.441

2.  A novel selective broad-spectrum anti-DNA virus agent.

Authors:  E De Clercq; A Holý; I Rosenberg; T Sakuma; J Balzarini; P C Maudgal
Journal:  Nature       Date:  1986 Oct 2-8       Impact factor: 49.962

3.  A mutant strain of varicella-zoster virus deficient in thymidine kinase-inducing activity.

Authors:  T Yokota; M Ogata; S Shigeta
Journal:  Fukushima J Med Sci       Date:  1983-07

4.  Isolation and characterisation of resistant Herpes simplex virus after acyclovir therapy.

Authors:  W H Burns; R Saral; G W Santos; O L Laskin; P S Lietman; C McLaren; D W Barry
Journal:  Lancet       Date:  1982-02-20       Impact factor: 79.321

5.  Strains of varicella-zoster virus resistant to 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.

Authors:  T Sakuma
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

6.  Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir.

Authors:  C S Crumpacker; L E Schnipper; S I Marlowe; P N Kowalsky; B J Hershey; M J Levin
Journal:  N Engl J Med       Date:  1982-02-11       Impact factor: 91.245

7.  Inhibitory effects of selected antiviral compounds on newly isolated clinical varicella-zoster virus strains.

Authors:  M Baba; K Konno; S Shigeta; E De Clercq
Journal:  Tohoku J Exp Med       Date:  1986-03       Impact factor: 1.848

8.  Characterization of a varicella-zoster virus variant with altered thymidine kinase activity.

Authors:  S Shigeta; S Mori; T Yokota; K Konno; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

Review 9.  Antiherpes drugs: promises and pitfalls.

Authors:  E de Clercq
Journal:  Eur J Clin Microbiol       Date:  1984-04       Impact factor: 3.267

10.  Comparative efficacy of antiherpes drugs against various strains of varicella-zoster virus.

Authors:  S Shigeta; T Yokota; T Iwabuchi; M Baba; K Konno; M Ogata; E De Clercq
Journal:  J Infect Dis       Date:  1983-03       Impact factor: 5.226
  10 in total
  6 in total

1.  Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo.

Authors:  E De Clercq; A Holý; I Rosenberg
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

2.  Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice.

Authors:  E De Clercq; A Holý
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

3.  Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus.

Authors:  G Andrei; R Snoeck; D Reymen; C Liesnard; P Goubau; J Desmyter; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

4.  Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine.

Authors:  J Balzarini; A Holy; J Jindrich; L Naesens; R Snoeck; D Schols; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

Review 5.  Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment.

Authors:  R Snoeck; G Andrei; E De Clercq
Journal:  Drugs       Date:  1999-02       Impact factor: 11.431

6.  Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection.

Authors:  Min Zhuang; Hong Jiang; Yasuhiro Suzuki; Xiaoguang Li; Peng Xiao; Takashi Tanaka; Hong Ling; Baofeng Yang; Hiroki Saitoh; Lianfeng Zhang; Chuan Qin; Kazuo Sugamura; Toshio Hattori
Journal:  Antiviral Res       Date:  2009-02-11       Impact factor: 5.970
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.